medigraphic.com
ISSN 2448-5640 (Impreso)
Diario Oficial de la Sociedad Mexicana de Cirugía Cardiaca, A.C., y del Colegio Mexicano de Cirugía Cardiovascular y Torácica, A.C.

2022, Número 4

Siguiente >>

Cir Card Mex 2022; 7 (4)


Chasm between the Guided-Directed Medical Therapy for functional mitral regurgitation used in the COAPT trial and present time: a major revision is mandatory

García-Villarreal OA

Idioma: Ingles.
Referencias bibliográficas: 28
Paginas: 61-64
Archivo PDF: 154.39 Kb.


FRAGMENTO

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure.Eur J Heart Fail. 2020 Aug;22(8):1342-1356. doi: 10.1002/ejhf.1858.

  2. Naser N. Clinical Implications of Functional Mitral Regurgitation Severity in Patientswith Heart Failure with Reduced Ejection Fraction (HFrEF). Med Arch.2022;76(1):17-22. doi: 10.5455/medarh.2022.76.17-22.

  3. Sharma H, Yuan M, Shakeel I, et al. A Longitudinal Study of Mitral RegurgitationDetected after Acute Myocardial Infarction. J Clin Med. 2022;11(4):965. doi:10.3390/jcm11040965.

  4. Sannino A, Smith RL 2nd, Schiattarella GG, Trimarco B, Esposito G, GrayburnPA. Survival and Cardiovascular Outcomes of Patients with SecondaryMitral Regurgitation: A Systematic Review and Meta-analysis. JAMA Cardiol.2017;2(10):1130-1139. doi: 10.1001/jamacardio.2017.2976.

  5. Benfari G, Antoine C, Essayagh B, et al. Functional Mitral Regurgitation Outcomeand Grading in Heart Failure with Reduced Ejection Fraction. JACC CardiovascImaging. 2021;14(12):2303-2315. doi: 10.1016/j.jcmg.2021.05.017.

  6. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for theManagement of Patients with Valvular Heart Disease: Executive Summary:A Report of the American College of Cardiology/American Heart AssociationJoint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb2;143(5):e35-e71. doi: 10.1161/CIR.0000000000000932.

  7. Stone GW, Lindenfeld J, Abraham WT, et al; COAPT Investigators. TranscatheterMitral-Valve Repair in Patients with Heart Failure. N Engl J Med.2018;379(24):2307-2318. doi: 10.1056/NEJMoa1806640.

  8. Iung B, Armoiry X, Vahanian A, et al; MITRA-FR Investigators. Percutaneous repairor medical treatment for secondary mitral regurgitation: outcomes at 2 years.Eur J Heart Fail. 2019;21(12):1619-1627. doi: 10.1002/ejhf.1616.

  9. Grayburn PA, Sannino A, Packer M. Proportionate and Disproportionate FunctionalMitral Regurgitation: A New Conceptual Framework That Reconcilesthe Results of the MITRA-FR and COAPT Trials. JACC Cardiovasc Imaging.2019;12(2):353-362. doi: 10.1016/j.jcmg.2018.11.006.

  10. Hagendorff A, Knebel F, Helfen A, Stöbe S, Doenst T, Falk V. Disproportionatemitral regurgitation: another myth? A critical appraisal of echocardiographicassessment of functional mitral regurgitation. Int J Cardiovasc Imaging. 2021Jan;37(1):183-196. doi: 10.1007/s10554-020-01975-6.

  11. De Bonis M, Lapenna E, Pozzoli A, Giacomini A, Alfieri O. Edge-to-edge surgicalmitral valve repair in the era of MitraClip: what if the annuloplasty ring is missed?Curr Opin Cardiol. 2015;30(2):155-160. doi: 10.1097/HCO.0000000000000148.

  12. De Bonis M, Lapenna E, Maisano F, et al. Long-term results (≤18 years) of theedge-to-edge mitral valve repair without annuloplasty in degenerative mitral regurgitation:implications for the percutaneous approach. Circulation. 2014;130(11Suppl 1):S19-24. doi: 10.1161/CIRCULATIONAHA.113.007885.

  13. De Bonis M, Lapenna E, Taramasso M, et al. Very long-term durability of the edgeto-edge repair for isolated anterior mitral leaflet prolapse: up to 21 years of clinicaland echocardiographic results. J Thorac Cardiovasc Surg. 2014;148(5):2027-32.doi: 10.1016/j.jtcvs.2014.03.041.

  14. De Bonis M, Taramasso M, Lapenna E, et al. MitraClip therapy and surgical edgeto-edge repair in patients with severe left ventricular dysfunction and secondarymitral regurgitation: mid-term results of a single-centre experience. Eur J CardiothoracSurg. 2016;49(1):255-62. doi: 10.1093/ejcts/ezv043.

  15. De Bonis M, Lapenna E, Buzzatti N, et al. Optimal results immediately after MitraCliptherapy or surgical edge-to-edge repair for functional mitral regurgitation:are they really stable at 4 years? Eur J Cardiothorac Surg. 2016 Sep;50(3):488-94.doi: 10.1093/ejcts/ezw093.

  16. Taramasso M, Denti P, Buzzatti N, et al. Mitraclip therapy and surgical mitralrepair in patients with moderate to severe left ventricular failure causing functionalmitral regurgitation: a single-centre experience. Eur J Cardiothorac Surg.2012;42(6):920-6. doi: 10.1093/ejcts/ezs294.

  17. Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prognostic significanceof heart failure stages: Application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation.2007;115(12):1563-1570. doi:10.1161/CIRCULATIONAHA.106.666818.

  18. How Long Can You Live with Heart Failure? Available at: https://www.verywellhealth.com/congestive-heart-failure-life-expectancy-prognosis-5089374#toc-prognosis-by-stage. Last addressed: July 10, 2022.

  19. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline forthe Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Circulation. 2022;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063.

  20. Nasser R, Van Assche L, Vorlat A, et al. Evolution of Functional Mitral Regurgitationand Prognosis in Medically Managed Heart Failure Patients with ReducedEjection Fraction. JACC Heart Fail. 2017;5(9):652-659. doi: 10.1016/j.jchf.2017.06.015.

  21. Kang DH, Park SJ, Shin SH, Hong GR, Lee S, Kim MS, Yun SC, Song JM, ParkSW, Kim JJ. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation. Circulation. 2019 Mar 12;139(11):1354-1365. doi: 10.1161/CIRCULATIONAHA.118.037077.

  22. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heartfailure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reducedand DAPA-HF trials. Lancet. 2020;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9.

  23. Bassi NS, Ziaeian B, Yancy CW, Fonarow GC. Association of Optimal Implementationof Sodium-Glucose Cotransporter 2 Inhibitor Therapy with Outcomefor Patients with Heart Failure. JAMA Cardiol. 2020;5(8):948-951. doi: 10.1001/jamacardio.2020.0898.

  24. Greene SJ, Khan MS. Quadruple Medical Therapy for Heart Failure: MedicationsWorking Together to Provide the Best Care. J Am Coll Cardiol. 2021;77(11):1408-1411. doi: 10.1016/j.jacc.2021.02.006.

  25. Greene SJ, Butler J, Albert NM, et al. Medical Therapy for Heart Failure withReduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol.2018;72(4):351-366. doi: 10.1016/j.jacc.2018.04.070.

  26. Ezekowitz JA. Residuals: Mitral Regurgitation, Bias, and Effects of MedicalTherapy. Circulation. 2021;144(6):438-440. doi: 10.1161/CIRCULATIONAHA.121.055707.

  27. Rezapour A, Azari S, Arabloo J, et al. . Cost-effectiveness analysis of mitral valverepair with the MitraClip delivery system for patients with mitral regurgitation: asystematic review. Heart Fail Rev. 2021;26(3):587-601. doi: 10.1007/s10741-020-10055-9.

  28. Heart valve disease presenting in adults: investigation and management. London:National Institute for Health and Care Excellence (NICE); 2021 Nov 17.(NICE Guideline, No. 208.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK577831/




2020     |     www.medigraphic.com